Reich K - Search Results

1

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.

Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V. Reich K, et al. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29. J Eur Acad Dermatol Venereol. 2018. PMID: 29220542 Free PMC article. Clinical Trial.

2

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Reich K, et al. Br J Dermatol. 2006 Jun;154(6):1161-8. doi: 10.1111/j.1365-2133.2006.07237.x. Br J Dermatol. 2006. PMID: 16704649 Clinical Trial.

3

Use of fumaric acid esters in psoriasis.

Roll A, Reich K, Boer A. Roll A, et al. Among authors: reich k. Indian J Dermatol Venereol Leprol. 2007 Mar-Apr;73(2):133-7. doi: 10.4103/0378-6323.31908. Indian J Dermatol Venereol Leprol. 2007. PMID: 17456929

4

Treatment goals in psoriasis.

Reich K, Mrowietz U. Reich K, et al. J Dtsch Dermatol Ges. 2007 Jul;5(7):566-74. doi: 10.1111/j.1610-0387.2007.06343.x. J Dtsch Dermatol Ges. 2007. PMID: 17610606 Review. English, German.

5

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Reich K, et al. Eur J Dermatol. 2007 Sep-Oct;17(5):381-6. doi: 10.1684/ejd.2007.0234. Epub 2007 Aug 2. Eur J Dermatol. 2007. PMID: 17673380 Clinical Trial.

6

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Rich P, et al. Among authors: reich k. J Am Acad Dermatol. 2008 Feb;58(2):224-31. doi: 10.1016/j.jaad.2007.07.042. Epub 2007 Dec 20. J Am Acad Dermatol. 2008. PMID: 18083272 Clinical Trial.

7

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Papp KA, et al. Among authors: reich k. Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6. Lancet. 2008. PMID: 18486740 Clinical Trial.

8

The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.

Reich K, Griffiths CE. Reich K, et al. Arch Dermatol Res. 2008 Nov;300(10):537-44. doi: 10.1007/s00403-008-0885-7. Epub 2008 Sep 11. Arch Dermatol Res. 2008. PMID: 18784934 Review.

9

Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.

Reich K, Krüger K, Mössner R, Augustin M. Reich K, et al. Br J Dermatol. 2009 May;160(5):1040-7. doi: 10.1111/j.1365-2133.2008.09023.x. Epub 2009 Feb 4. Br J Dermatol. 2009. PMID: 19210498

10

Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE).

Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Reich K, et al. J Dtsch Dermatol Ges. 2009 Jul;7(7):603-11. doi: 10.1111/j.1610-0387.2009.07120.x. Epub 2009 May 4. J Dtsch Dermatol Ges. 2009. PMID: 19459898 English, German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

584 results

Search Page